Prostatype Genomics AB (OSTO:PROGEN) Total Assets: kr50.86 Mil (As of Dec. 2025)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.36
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Total Assets?

Prostatype Genomics AB OSTO:PROGEN -9.32% 25 Total Assets is kr50.86 Mil as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Prostatype Genomics AB's Total Assets for the quarter that ended in Dec. 2025 was kr50.86 Mil.

During the past 12 months, Prostatype Genomics AB's average Total Assets Growth Rate was 28.40% per year. During the past 3 years, the average Total Assets Growth Rate was 29.00% per year. During the past 5 years, the average Total Assets Growth Rate was 24.00% per year.

During the past 7 years, Prostatype Genomics AB's highest 3-Year average Total Assets Growth Rate was 46.20%. The lowest was 17.90%. And the median was 24.10%.

Total Assets is connected with ROA %. Prostatype Genomics AB's annualized ROA % for the quarter that ended in Dec. 2025 was -86.94%. Total Assets is also linked to Revenue through Asset Turnover. Prostatype Genomics AB's Asset Turnover for the quarter that ended in Dec. 2025 was 0.01.

Prostatype Genomics AB  (OSTO:PROGEN) Total Assets Explanation

Total Assets is connected with ROA %.

Prostatype Genomics AB's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-41.166/( (43.84+50.862)/ 2 )
=-41.166/47.351
=-86.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Prostatype Genomics AB's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.348/( (43.84+50.862)/ 2 )
=0.348/47.351
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Prostatype Genomics AB Total Assets Related Terms

Prostatype Genomics AB Total Assets Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Total Assets Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 40.20 30.95 49.22 41.97 50.86

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.22 32.27 41.97 43.84 50.86
OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Prostatype Genomics AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=26.53+24.332
=50.86

Prostatype Genomics AB's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=26.53+24.332
=50.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr50.86 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Total Assets of kr50.86 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Total Assets too high?
Prostatype Genomics AB's current Total Assets is kr50.86 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Total Assets compare to TMO and DHR?
Prostatype Genomics AB's Total Assets of kr50.86 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Total Assets is kr50.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.36 — trading 227.3% above its estimated fair value. The current Total Assets is kr50.86 Mil. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Total Assets is kr50.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.36 is trading 227.3% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Total Assets: kr50.86 Mil
  • GF Value™: kr0.11 vs. price of kr0.36 (227.3% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.36
Price
kr0.11
GF Value